Navigation Links
Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
Date:7/12/2010

PALO ALTO, Calif., July 12 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html.  This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.  Telintra®, Telik's investigational drug candidate inhibitor of GSTP1-1, has recently been reported to show positive results in a Phase 2 trial in patients with MDS, a disease characterized by disordered cell proliferation and differentiation.  Reprints of the publication are available from Telik.  

Background on MDS

The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis (blood cell production) involving one or more cell lineages (red blood cells, white blood cells or platelets) and a variable risk of transformation to acute myeloid leukemia (AML).  MDS becomes more common with age.  It is estimated that MDS affects approximately 300,000 people worldwide.  According to the American Cancer Society, 10,000–20,000 new cases of MDS are diagnosed each year in the United States, with survival rates ranging from six months to six years.  MDS patients often require blood transfusions to manage their disease.

There remains a critical need for effective, well tolerated therapies for MDS.  Telintra has a novel mechanism of action that inhibits an enzyme called glutathione S-transferase P1-1 which may activate JNK kinase, a key regulator of cellular growth and differentiation of blood precursor cells.  Telintra has been shown to stimulate normal multilineage differentiation of blood stem cell precursors and induce cancer cell death, or apoptosis, in human leukemia cell lines.  Additional information on Telintra is available at www.telik.com.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidates in clinical development are Telintra, a modified glutathione analog for the treatment of MDS and Severe Chronic Neutropenia (SCN), and Telcyta®, a cancer activated prodrug for the treatment of advanced non-small cell lung cancer and ovarian cancer.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Telik Announces Publication of a Case Report of a Sustained Hematologic Response in Myelodysplastic Syndrome Following an Abbreviated Exposure to Oral Telintra(R) (Ezatiostat HCl)
2. Telik Announces Fourth Quarter and 2009 Year End Financial Results and 2010 Financial Guidance
3. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
4. Telik Announces Third Quarter 2009 Financial Results
5. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
6. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
7. Telik Announces Presentation at ASCO Annual Meeting
8. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
9. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
10. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
11. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... , May 18, 2017  Two Bayer U.S. ... Association (HBA) during its recent 28 th ... City.  The event showcases HBA,s longstanding mission of furthering ... of healthcare. Cindy Powell-Steffen , senior ... U.S. Radiology division, and Libby Howe , a ...
(Date:5/12/2017)... 12, 2017  The China and Canada ... consumes less water, energy and detergent, and features a powerful disinfection ... a shoebox-sized washing machine that washes and sanitizes women,s panties or ... ... compact, and does not require an external water inlet. ...
(Date:5/10/2017)... -- The Corporate Whistleblower Center says, "We are urging ... to call us anytime at 866-714-6466 if they possess ... a substantial scheme to overbill Medicare. We are ... of a medical equipment company if their employer ... practice groups with extra generous incentives to use, or ...
Breaking Medicine Technology:
(Date:5/21/2017)... ... May 21, 2017 , ... For more than 20 ... a wide range of knives and swords, from functional to fantasy. United Cutlery has ... with sleek, modern designs that defy tradition. , Offering a range of weapons and ...
(Date:5/19/2017)... ... ... In a continuous effort to raise awareness of autism and common toxins ... in natural and organic latex mattresses, has announced that they will donate $1 to ... their recent viral Facebook video receives, up to $10,000.00. , The luxury ...
(Date:5/19/2017)... Mo (PRWEB) , ... May 19, 2017 , ... When ... May 20, his name will already appear on two major research studies that could ... been working with Dr. Matt Daggett, KCU alumnus and an orthopedic surgeon, alongside an ...
(Date:5/19/2017)... ... May 19, 2017 , ... ... retirement planning assistance to families and business owners in the region, is embarking ... for MS sufferers and their families. , Multiple sclerosis (MS) is a demyelinating ...
(Date:5/19/2017)... Atlanta, GA (PRWEB) , ... May 19, 2017 , ... ... D. Miller knows the importance of prostate cancer screenings. Early detection of the ... Miller, head of robotic surgery at Georgia Urology , stands alongside the Georgia ...
Breaking Medicine News(10 mins):